2026, Packaging and Vaccine - Drug Discovery Digest

Elliott Advisors (UK) letter to GSK

The Pharma Data

JULY 6, 2021

At its Investor Update, GSK announced a package of new financial outlooks and ambitions. Adjusted operating margins are expected to improve from the current mid-20s level to over 30% by 2026. Cash generated from operations is expected to exceed £10 billion by 2026.

Government

Government Vaccine Production Science

Fujifilm to Invest Over 200 Billion yen (2 Billion USD) to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.

The Pharma Data

JANUARY 6, 2021

End-to-End Single-Site Solution from Drug Substances to Fill-Finish & Packaging. In addition to drug substance manufacture, the facility will also provide commercial scale, automated fill-finish and assembly, packaging and labeling services. Packaging line?. TOKYO , Jan. 8 x 20,000L bioreactors for mammalian cells.

Packaging

Packaging Small Molecule Production FDA Approval

Article FDA Thank You FDA updates set the stage for broader use of harmonized standards for safety reporting

Agency IQ

APRIL 8, 2024

While the SRP could be used to submit information on drugs and biological products, the only exception was for vaccines. Sponsors will have 24 months to get comfortable submitting IND safety reports in E2B(R3) format before compliance becomes mandatory in April 2026.

FDA

FDA Production Regulations Vaccine

Elliott Advisors (UK) letter to GSK

Fujifilm to Invest Over 200 Billion yen (2 Billion USD) to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.

Article FDA Thank You FDA updates set the stage for broader use of harmonized standards for safety reporting

Stay Connected